A Phase 2 interventional study of Dihydroartemisinin tablet and Placebo tablet in Systemic Lupus Erythematosus, sponsored by Kunming Pharmaceuticals, Inc.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Kunming Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to assess the efficacy of DHA in patients with SLE.
This is a Phase 2, multicentre, randomised, double-blind, placebo-controlled study to evaluate the Safety, Pharmacokinetics and Efficacy of four oral treatment regimens of DHA versus placebo while taking standard of care (SOC) treatment with corticosteroids in adult subjects with Systemic Lupus Erythematosus (SLE).
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
This study's planned enrollment of 120 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Browse Lupus Erythematosus, Systemic studies →Kunming Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.
Drug: Dihydroartemisinin tablet
Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.
Drug: Dihydroartemisinin tablet
Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.
Drug: Dihydroartemisinin tablet
Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.
Drug: Placebo tablet
DHA tablet
Also known as: No other names
Placebo tablet
Also known as: No other names
SRI,Response at Week 24 according to a combined response index
The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, and treatment failure status.
Time frame: week 24
Change from baseline in SLEDAI score
Change from baseline in SLEDAI score at week 4,8,12,16,20,24
Time frame: week 4,8,12,16,20,24
Change from baseline in PAG score
Change from baseline in PAG score at week 4,8,12,16,20,24
Time frame: week 4,8,12,16,20,24
Number of days of daily prednisone dose Less than or equal to 7.5 mg/day
Number of days of daily prednisone dose Less than or equal to 7.5 mg/day from baseline over 24 weeks
Time frame: Baseline, Week 24
Percent of subjects with UPRO <0.5g/24h
Percent of subjects with UPRO \<0.5g/24h from baseline at Week 4,12,24
Time frame: Week 4,12,24
No study locations are listed for this record.
Plan to share: Undecided — This study has not been decided.
No publications or documents are linked to this record.
Start is estimated for Mar 2018; primary completion for Dec 2021, 45 months later.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 45 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Artenimol
Lupus Erythematosus, Systemic →
Kunming Pharmaceuticals, Inc.